6.3 Fibrinolytic Therapy & Blood Pressure Management

Fibrinolytic Therapy & Blood Pressure Management

Intravenous Fibrinolytic Therapy

Intravenous (IV) fibrinolytic therapy, commonly referred to as thrombolysis, remains the primary medical intervention and the cornerstone of acute ischemic stroke management for eligible patients. The medications utilized in this therapy—most notably alteplase (recombinant tissue plasminogen activator, or rtPA) and increasingly tenecteplase (TNK)—are powerful pharmacological agents. They act fundamentally as "clot-busters" by binding to fibrin within the thrombus and rapidly converting entrapped plasminogen to plasmin. Plasmin is a potent enzyme that systematically degrades the fibrin matrix of the clot, leading to its dissolution. Prompt and successful administration of these agents can restore vital cerebral blood flow to the ischemic penumbra, thereby preventing further infarction and significantly improving the patient's long-term functional and neurological outcomes.

The Strict Treatment Time Windows

The therapeutic efficacy of IV fibrinolytics is intrinsically linked to time. The window for administration is exceedingly narrow and strictly enforced:

• Standard FDA-Approved Window: The standard window for administering IV fibrinolytic therapy is within 3 hours of the patient's established Last Known Well (LKW) time.
• Extended Window: Based on robust clinical trial data, this window can be extended up to 4.5 hours from the LKW time for a carefully selected, highly specific subset of eligible patients.

Attempting to administer IV fibrinolytics beyond the 4.5-hour mark is generally contraindicated. As time passes from the initial onset of ischemia, the blood-brain barrier becomes increasingly compromised, and the infarcted brain tissue becomes highly friable. Administering a powerful thrombolytic late in the process dramatically increases the risk of hemorrhagic transformation—a catastrophic event where severe bleeding occurs directly into the damaged brain tissue, often proving fatal. Therefore, beyond 4.5 hours, the risks of therapy massively outweigh any potential benefits.

Inclusion and Exclusion Criteria

Before proceeding with the administration of a powerful thrombolytic, the clinical team must rigorously execute a comprehensive checklist of absolute and relative contraindications. The overarching goal of this screening process is to meticulously identify patients who possess an unacceptably high risk of catastrophic bleeding complications.

Critical Exclusion Criteria

The exclusion criteria are extensive, but several key factors universally preclude the use of IV fibrinolytics:

• Recent Head Trauma or Prior Stroke: Any significant head trauma or previous ischemic stroke occurring within the preceding 3 months constitutes a high risk for bleeding.
• Active or History of Bleeding: Any active internal bleeding, a known history of prior intracranial hemorrhage, or a known bleeding diathesis.
• Recent Major Surgery: Any major surgical procedure or significant physical trauma within the last 14 days.
• Coagulopathy and Anticoagulant Use: A baseline platelet count of < 100,000/mm³, an elevated INR > 1.7, or an elevated aPTT. Crucially, the current use of Direct Oral Anticoagulants (DOACs, such as apixaban or rivaroxaban) within the last 48 hours strongly contraindicates therapy unless specific, sensitive laboratory assays (e.g., anti-factor Xa levels) prove the drug has cleared the system.
• Severe, Uncontrolled Hypertension: Sustained Systolic Blood Pressure (SBP) > 185 mmHg or Diastolic Blood Pressure (DBP) > 110 mmHg that cannot be safely and rapidly lowered with medication.
• Suspicion of Subarachnoid Hemorrhage: If the clinical presentation suggests a subarachnoid hemorrhage (e.g., sudden "thunderclap" headache), fibrinolytics are contraindicated even if the initial CT scan is completely negative for blood.

Blood Pressure Management in Acute Stroke

Blood pressure control is arguably one of the most challenging, dynamic, and critical aspects of acute stroke management. During an acute ischemic stroke, the brain's innate ability to autoregulate its own blood flow is severely impaired. Consequently, cerebral perfusion becomes directly, linearly dependent on systemic blood pressure. While a moderately elevated blood pressure is often a physiological compensatory mechanism designed to push blood through collateral vessels to save the ischemic penumbra, excessively high blood pressure dramatically amplifies the risk of intracranial hemorrhage—especially when the vascular system is subjected to fibrinolytic agents.

Blood Pressure Targets BEFORE Fibrinolytic Therapy

If a patient meets all other criteria for IV fibrinolytics, but their presenting blood pressure is severely elevated, the clinical team must cautiously lower it before treatment can commence.

• Mandatory Target BEFORE administration: Systemic blood pressure must be stabilized at SBP < 185 mmHg and DBP < 110 mmHg.
• If the blood pressure stubbornly remains above 185/110 mmHg despite aggressive, appropriate medical management, the patient is deemed ineligible for fibrinolytic therapy due to the extreme risk of bleeding.

Pharmacologic agents utilized in this hyper-acute setting must have a rapid onset and a short half-life to allow for precise titration. Commonly used intravenous medications include labetalol (a mixed alpha/beta-adrenergic antagonist), nicardipine (a calcium channel blocker), and clevidipine (an ultra-short-acting calcium channel blocker). These agents allow clinicians to rapidly lower the blood pressure without overshooting into dangerous hypotension, which would further starve the brain of oxygen.

Blood Pressure Targets AFTER Fibrinolytic Therapy

Once the decision is made and the fibrinolytic infusion is initiated, the patient enters a high-risk phase where the potential for bleeding is at its absolute peak. Strict, continuous blood pressure monitoring and rigorous control are absolutely mandated.

• Mandatory Target AFTER administration: For at least the first 24 hours post-infusion, blood pressure must be rigorously maintained at SBP < 180 mmHg and DBP < 105 mmHg.
• To ensure compliance, blood pressure must be monitored utilizing a highly standardized frequency protocol: every 15 minutes for the first 2 hours, then every 30 minutes for the next 6 hours, and finally hourly for the remaining 16 hours of the 24-hour window.

Antithrombotic Avoidance Post-Treatment

To further mitigate the profound risk of intracranial hemorrhage following thrombolysis, an absolute moratorium is placed on additional blood-thinning agents. No other antithrombotic medications—including aspirin, clopidogrel, ticagrelor, or any form of therapeutic heparin—should be administered for at least 24 hours following the completion of the fibrinolytic infusion. After 24 hours have elapsed, a follow-up non-contrast head CT or MRI is routinely obtained to definitively confirm the absence of any new bleeding before antiplatelet or anticoagulant therapies are initiated to prevent secondary strokes.